We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

179 hedge funds and large institutions have $1.21B invested in Sarepta Therapeutics in 2017 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $108M | Put options by funds: $54.9M

45% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 44

39% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 28

11% more capital invested

Capital invested by funds: $1.08B → $1.21B (+$123M)

2.09% more ownership

Funds ownership: 72.29% → 74.38% (+2.1%)

1% more funds holding

Funds holding: 177 → 179 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
179
Holders Change
+2
Holders Change %
+1.13%
% of All Funds
4.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
39
Increased
64
Reduced
44
Closed
28
Calls
$108M
Puts
$54.9M
Net Calls
+$53.5M
Net Calls Change
+$36.4M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$160M
2
HM
HealthCor Management
New York
+$48M
3
CCM
Camber Capital Management
Massachusetts
+$41.8M
4
O
OrbiMed
New York
+$32.6M
5
PC
PointState Capital
New York
+$19.8M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$62.4M
2
PA
Perceptive Advisors
New York
-$30.9M
3
ACA
Avoro Capital Advisors
New York
-$27.7M
4
JG
Jefferies Group
New York
-$26M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
GPCM
101
Granite Point Capital Management
Massachusetts
$692K -$1.13M -36,630 -61%
OC
102
Oppenheimer & Co
New York
$674K +$705K +22,772 New
VOYA Investment Management
103
VOYA Investment Management
Georgia
$583K – – –
Ameriprise
104
Ameriprise
Minnesota
$544K +$566K +18,297 +117%
Royal Bank of Canada
105
Royal Bank of Canada
Ontario, Canada
$538K +$372K +12,009 +195%
PP
106
Paloma Partners
Connecticut
$527K -$70.5K -2,278 -11%
First Trust Advisors
107
First Trust Advisors
Illinois
$526K -$330K -10,673 -38%
JCM
108
Jafra Capital Management
New York
$518K +$309K +10,000 +133%
Legal & General Group
109
Legal & General Group
United Kingdom
$498K -$6.87K -222 -1%
D.E. Shaw & Co
110
D.E. Shaw & Co
New York
$449K -$449K -14,506 -49%
JCP
111
Jabre Capital Partners
Switzerland
$444K +$464K +15,000 New
GGHC
112
Gilder Gagnon Howe & Co
New York
$434K +$117K +3,774 +35%
TD Asset Management
113
TD Asset Management
Ontario, Canada
$423K -$27.9K -900 -6%
Stifel Financial
114
Stifel Financial
Missouri
$397K +$67K +2,165 +19%
FRM
115
Fox Run Management
Connecticut
$388K +$405K +13,100 New
CD
116
Carl Domino
Florida
$385K – – –
SPC
117
Sigma Planning Corp
Michigan
$382K +$28.8K +930 +8%
SSA
118
Schonfeld Strategic Advisors
New York
$355K +$57.9K +1,872 +19%
RJFSA
119
Raymond James Financial Services Advisors
Florida
$333K +$98.2K +3,173 +39%
ST
120
Spot Trading
Illinois
$323K -$84K -2,715 -20%
Public Employees Retirement Association of Colorado
121
Public Employees Retirement Association of Colorado
Colorado
$312K – – –
VKH
122
Virtu KCG Holdings
New York
$307K +$321K +10,361 New
GAMA
123
Graticule Asia Macro Advisors
New York
$306K – – –
AG
124
Advisor Group
Arizona
$298K +$9.75K +315 +3%
ECM
125
Ensemble Capital Management
California
$296K +$309K +10,000 New
3 4
5
6 7

SRPT Hedge Fund Activity: Q1 2017 in Review

179 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2017, worth a combined $1.21B — up 11% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SRPT positions and 28 closed out — a net gain of 11 holders — while 64 added to existing stakes and 44 trimmed.

The largest buyer was BlackRock, adding an estimated $160M. The largest seller was Sabby Management, exiting entirely with an estimated $62.4M sold.

  • 179 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2017, up from 177 in Q4 2016.
  • Funds reported $1.21B of Sarepta Therapeutics stock for Q1 2017, up 11% quarter-over-quarter.
  • 39 funds opened new Sarepta Therapeutics positions in Q1 2017 and 28 closed out, a net change of +11 holders.
  • The largest Sarepta Therapeutics buyer in Q1 2017 was BlackRock, an estimated $160M added.
  • The largest Sarepta Therapeutics seller in Q1 2017 was Sabby Management, an estimated $62.4M sold.

Based on aggregated 13F filings for Q1 2017.